A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma

Journal of Hand Surgery: European Volume

Volumn 39, Issue 8, 2014, Pages 876-880

  Uppal, L ^a   Dhaliwal, K ^a   Butler, P E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Botulinum toxin; Raynaud's; scleroderma; sympathectomy

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; COMPLICATION; DISABILITY; FEMALE; HAND STRENGTH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; JOINT CHARACTERISTICS AND FUNCTIONS; MIDDLE AGED; PROSPECTIVE STUDY; RAYNAUD DISEASE; SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE; YOUNG ADULT;

ADULT; BOTULINUM TOXINS, TYPE A; DISABILITY EVALUATION; FEMALE; HAND STRENGTH; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84908150933     PISSN: 17531934     EISSN: 20436289     Source Type: Journal    
DOI: 10.1177/1753193413516242     Document Type: Article

References (18)

1. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002 ; 18: S177-81
2. Carroll I, Clark JD, Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neuro. 2009 ; 65: 348-51
3. Clemens MW, Higgins JP, Shaw Wilgis EF. Prevention of anastomotic thrombosis by botulinum toxin A in an animal model. Plast Reconstr Surg. 2009 ; 123: 64-70
4. Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischaemia in patients with Raynaud's phenomenon. J Hand Surg Am. 2009 ; 34: 446-52
5. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol. 2000 ; 12: 527-33
6. Herron GS, Romero LI. Vascular abnormalities in scleroderma. Semin Cutan Med Surg. 1998 ; 17: 12-7
7. Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for the treatment of chronic digital ischaemia. J Rheumatol. 2003 ; 30: 1788-92
8. McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: Clues to the locus of action. J Biol Chem. 1992 ; 267: 21338-43
9. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol. 2001 ; 281: H2124-32
10. Murata K, Omokawa S, Kobata Y, Tanaka Y, Yajima H, Tamai S. Long-term follow-up of periarterial sympathectomy for chronic digital ischaemia. J Hand Surg Eur. 2012 ; 37: 788-93
11. Neumeister MW, Chambers CB, Herron MS, et al. Botox therapy for ischaemic digits. Plast Reconstr Surg. 2009 ; 124: 191-200
12. Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 ; 35: 2085-92
13. Ovens L, Dewar D. Use of botulinum toxin in complex regional pain syndrome in the hand. Eur J Plast Surg. 2013 ; 36: 37-9
14. Sandqvist G, Hesslestrand R, Eberhardt K. A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis. Scand J Rheumatol. 2009 ; 38: 304-10
15. Setler P. Therapeutic use of botulinum toxins: Background and history. Clin J Pain. 2002 ; 18: S119-24
16. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Euro J Clin Invest. 2004 ; 34: 312-3
17. Tsai CP, Liu CY, Lin KP, Wang KC. Efficacy of botulinum toxin type A in the relief of carpal tunnel syndrome: A preliminary experience. Clin Drug Invest. 2006 ; 26: 511-5
18. Van Beek AL, Lim PK, Gear A, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007 ; 119: 217-26